Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19

Group A and B Inclusion Criteria: 1. Verified COVID-19 2. Hospital admitted 3. Daily administration of RAS-inhibiting therapy 4. Age 18 years and above 5. Informed consent Exclusion Criteria: 1. Diagnosed with systolic heart failure (heart failure with reduced ejection fraction) 2. Severe kidney disease; defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m2 3. Severe hypertension; defined by systolic pressure \>175 mm Hg and/or diastolic pressure \>105 mm Hg 4. Hypotension; defined by systolic pressure \<100 mm Hg and/or diastolic pressure \<60 mm Hg 5. Non-compliance of RAS-inhibiting therapy; defined as an estimated adherence \<80% assessed by a questionnaire in combination with checking the Danish electronic medication system "FMK" (obligatory for clinicians in Denmark to ensure the Danish electronic medication system "FMK" is correct and up-to-date) for redeemed prescriptions in the last six months; in borderline cases, the participant is assumed compatible 6. Pregnancy or breastfeeding 7. Contra indications for receiving ACE inhibitors or ARBs: 1. Severe liver disease 2. Hypersensitivity or allergic reactions to the therapy 3. Angioneurotic edema during previous treatments 4. Family history of or previous idiopathic angioneurotic edema 5. Treatment with sacubitril/valsartan or aliskiren Group C and D: Inclusion Criteria: 1. Daily administration of RAS-inhibiting therapy 2. Age 18 years and above 3. Informed consent Exclusion Criteria: 1. Diagnosed with systolic heart failure (heart failure with reduced ejection fraction) 2. Severe kidney disease; defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m2 3. Severe hypertension; defined by systolic pressure \>175 mm Hg and/or diastolic pressure \>105 mm Hg 4. Hypotension; defined by systolic pressure \<100 mm Hg and/or diastolic pressure \<60 mm Hg 5. Non-compliance of RAS-inhibiting therapy; defined as an estimated adherence \<80% assessed by a questionnaire in combination with checking the Danish electronic medication system "FMK" (obligatory for clinicians in Denmark to ensure the Danish electronic medication system "FMK" is correct and up-to-date) for redeemed prescriptions in the last six months; in borderline cases, the participant is assumed compatible 6. Pregnancy or breastfeeding 7. Contra indications for receiving ACE inhibitors or ARBs: 1. Severe liver disease 2. Hypersensitivity or allergic reactions to the therapy 3. Angioneurotic edema during previous treatments 4. Family history of or previous idiopathic angioneurotic edema 5. Treatment with sacubitril/valsartan or aliskiren